48 results
8-K
EX-99.2
NVTAQ
Invitae Corp
1 Apr 20
Invitae Announces Proposed Public Offering of Common Stock
4:34pm
of the ongoingCOVID-19 pandemic. There can be no assurance that these estimates will be realized, and estimates are subject to risks and uncertainties, many … expect it to have a material impact on our financial results for at least the next quarter and potentially the full year. In response to the pandemic we
8-K
NVTAQ
Invitae Corp
1 Apr 20
Regulation FD Disclosure
4:39pm
and potentially the full year. In response to the pandemic, the Company has implemented measures to protect the health of all employees during this time … Reform Act of 1995, including but not limited to: statements regarding the impact of the COVID-19 pandemic on the Company’s business and financial
8-K
EX-99.1
NVTAQ
Invitae Corp
12 Jan 21
Invitae Reports Preliminary 2020 Financial Results of More Than $278 Million in Revenue and More Than 655,000 in Billable Volume
6:06am
in light of the impact of the COVID-19 pandemic on the healthcare system throughout the year,” said Sean George, Ph.D., co-founder and chief …
Outlook for 2021
Looking ahead to 2021 and factoring in the continued impact associated with the COVID-19 pandemic, Invitae reiterates its stated outlook
8-K
EX-99.1
NVTAQ
Invitae Corp
5 May 20
Invitae Reports More Than $64 Million in Revenue Driven by More Than 154,000 Samples Accessioned in the First Quarter of 2020
4:11pm
momentum as we began experiencing impacts from the pandemic. As healthcare has shifted, we have been able to quickly leverage our pre-existing … support for clinicians transitioning to telehealth (see below)
The impact of the pandemic on testing volume has and is likely to continue to vary based
424B5
NVTAQ
Invitae Corp
3 Apr 20
Prospectus supplement for primary offering
12:00am
of the fiscal year ending December 31, 2020 or in any future period, in particular due to the impact of the ongoingCOVID-19 pandemic. There can … the next quarter and potentially the full year. In response to the pandemic we have implemented measures to protect the health of all of our employees during
424B5
cqq2a6 dv
1 Apr 20
Prospectus supplement for primary offering
5:05pm
8-K
EX-99.1
ycux9z
4 Aug 20
Invitae Reports $46.2 Million in Revenue Driven by More Than 120,000 Samples Accessioned in the Second Quarter of 2020
4:13pm
8-K
0044pq1p7723qx1mw
1 Apr 20
Invitae Announces Proposed Public Offering of Common Stock
4:34pm
8-K
ytj64bfpdppi3vitv
20 Jan 21
Invitae Announces Proposed Public Offering of Common Stock
4:10pm
8-K
EX-99.2
qyr4iye9lalz
20 Jan 21
Invitae Announces Proposed Public Offering of Common Stock
4:10pm
8-K/A
EX-99.2
c8gm1vu
23 Nov 20
Consolidated Financial Statements
12:00am
424B5
8p1lni25ms
25 Jan 21
Prospectus supplement for primary offering
4:02pm
424B5
imaxnvaa2
20 Jan 21
Prospectus supplement for primary offering
4:24pm
8-K
EX-99.2
pohb axm562
22 Jun 20
Invitae and ArcherDX to create a global leader in comprehensive cancer genetics and precision oncology
4:55pm
8-K
EX-99.1
qx8uzpgx g0rj
17 Feb 21
Invitae Reports $279.6 Million in Annual Revenue Driven by 659,000 in Billable Volume in 2020
4:09pm